Companies · Biotechnology

Permeaderm, Inc.

CARLSBAD · Biotechnology

Diligence memoA one-page analyst read on Permeaderm, Inc. — recommendation, valuation, rhythm, risks.
$1.4M
Total raised · real
4
Rounds
0.6×
Latest step-up
Top 78%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Sun Jul 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Permeaderm, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.31× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era.
  • Within the normal band (131% of peer median) for its niche.
Dormant
  • Last raise 8.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Permeaderm, Inc. is one of 4291 Biotechnology companies tracked from CARLSBAD. By capital raised it ranks in the long tail (ahead of 23% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$0–$1M
Issuer revenue
Rule 504
Reg D exemption
2013
Year incorporated
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2016-07-01 Raised $250K (real) Modeled valuation $14M (est)$250K$14MPre-Seed2016Pre-Seed · 2016-07-01 Raised $350K (real) Modeled valuation $19M (est)$350K$19MPre-Seed2016Pre-Seed · 2017-07-01 Raised $350K (real) Modeled valuation $19M (est)$350K$19MPre-Seed2017Pre-Seed · 2017-07-01 Raised $250K (real) Modeled valuation $14M (est)$250K$14MPre-Seed2017Pre-Seed · 2018-07-01 Raised $500K (real) Modeled valuation $28M (est)$500K$28MPre-Seed2018Pre-Seed · 2018-07-01 Raised $300K (real) Modeled valuation $17M (est)$300K$17MPre-Seed2018+$350K+$350K+$250K+$500K+$300KCumulative $2.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$250K · 2016
Pre-Seed extension$350K · 2016
Pre-Seed extension$350K · 2017
Pre-Seed extension$250K · 2017
Pre-Seed extension$500K · 2018
Pre-Seed extension$300K · 2018

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$27.6M
Base estimate est.
$267K
Conservative case
$313.0M
Upside case
$2.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $13.8M · 2016-07-012016Pre-Seed · modeled $19.3M · 2016-07-01Pre-Seed · modeled $19.3M · 2017-07-01Pre-Seed · modeled $13.8M · 2017-07-01Pre-Seed · modeled $27.6M · 2018-07-01Pre-Seed · modeled $16.6M · 2018-07-012018
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
8.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
5 mo
Avg between rounds
$725K/yr
Capital velocity
10.0 yr
On record since
2016
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.2× of median
This company$1.4M
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.7× of median
This company$300K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$27.6M
Sector median$64.2M

Raised more than 23% of sector peers (real $). Modeled value above 34% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #59 of 152.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Cerebral Magnetics INC · Pre-Seed Raised $1.0M · modeled $55.2M (est)AnTolRx, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)NutriBand Inc. · Pre-Seed Raised $1.2M · modeled $55.2M (est)US Biologic, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)New Vital Signs, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Jivana Biotechnology Inc · Pre-Seed Raised $2.0M · modeled $55.2M (est)Zeta Biolongevity, Inc. · Pre-Seed Raised $995K · modeled $54.9M (est)ALRGN Bio, Inc. · Pre-Seed Raised $946K · modeled $52.2M (est)BioSurfaces, LLC · Pre-Seed Raised $900K · modeled $49.7M (est)Cellsolutions Llc · Pre-Seed Raised $1.9M · modeled $49.7M (est)Pique Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $47.2M (est)NeuExCell Therapeutics Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)Permeaderm, Inc. (this company) Raised $1.4M · modeled $27.6M (est)Permeaderm, Inc.
CompanyStageRaised · realValue · estvs peer med.
Cerebral Magnetics INCPre-Seed$1.0M$55.2M2.61×
AnTolRx, Inc.Pre-Seed$1.0M$55.2M2.61×
NutriBand Inc.Pre-Seed$1.2M$55.2M2.61×
US Biologic, Inc.Pre-Seed$1.0M$55.2M2.61×
New Vital Signs, Inc.Pre-Seed$1.0M$55.2M2.61×
Jivana Biotechnology IncPre-Seed$2.0M$55.2M2.61×
Zeta Biolongevity, Inc.Pre-Seed$995K$54.9M2.60×
ALRGN Bio, Inc.Pre-Seed$946K$52.2M2.47×
BioSurfaces, LLCPre-Seed$900K$49.7M2.35×
Cellsolutions LlcPre-Seed$1.9M$49.7M2.35×
Pique Therapeutics, Inc.Pre-Seed$1.4M$47.2M2.23×
NeuExCell Therapeutics Inc.Pre-Seed$850K$46.9M2.22×
Permeaderm, Inc. this companyPre-Seed$1.4M$27.6M1.31×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$250K2016-07-01$1.4M$13.8M85%
Pre-Seed$350K2016-07-01$1.9M$19.3M85%
Pre-Seed$350K2017-07-01$1.9M$19.3M90%
Pre-Seed$250K2017-07-01$1.4M$13.8M90%
Pre-Seed$500K2018-07-01$2.8M$27.6M90%
Pre-Seed$300K2018-07-01$1.7M$16.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$250K2016-07-01
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$350K2016-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× larger than the prior — scaling up.
  3. Pre-Seed$350K2017-07-01
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  4. Pre-Seed$250K2017-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× smaller than the prior — bridge or down round.
  5. Pre-Seed$500K2018-07-01
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
  6. Pre-Seed$300K2018-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× smaller than the prior — bridge or down round.
Intelligence
2018 ~Q4
Modeled next raise · ~5mo cadence
$300K
Modeled next size est.range $300K$480K
0.6×
Last step-up
$725K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
E. Aubrey Woodroof2016-07
Laverne Aubrey Martin2018-07
Scott Aubrey Moote2018-07
Registry & provenance

Permeaderm, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1577529
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
BioMedomics, Inc.BiotechnologyPre-Seed$1.5M$29.3Msame sector · same stage
Photoswitch Biosciences, Inc.BiotechnologyPre-Seed$1.5M$27.6Msame sector · same stage
AIT Bioscience, LLCBiotechnologyPre-Seed$1.5M$27.6Msame sector · same stage
GenomeNext LLCBiotechnologyPre-Seed$1.5M$27.6Msame sector · same stage
Techulon IncBiotechnologyPre-Seed$1.4M$21.8Msame sector · same stage
Euclid Systems CorpBiotechnologyPre-Seed$1.5M$26.3Msame sector · same stage
CoreBiome, Inc.BiotechnologyPre-Seed$1.4M$30.4Msame sector · same stage
CanDiag, Inc.BiotechnologyPre-Seed$1.6M$25.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
BiomeSense, Inc.BiotechnologySeries A$22.4M86%
Perimetrics, Inc.BiotechnologySeries A$60.4M86%
Biomea Fusion, Inc.BiotechnologySeries C$1.9B85%
Perlumi Chemicals, Inc.BiotechnologySeries A$25.2M85%
PhenoBiome, Inc.BiotechnologySeed$18.3M85%
Portal Biotechnologies, Inc.BiotechnologySeries A$49.5M84%
Purigen Biosystems, Inc.BiotechnologySeries B$1.4B84%
Metagenomi Technologies, LLCBiotechnologySeries D+$1.7B83%
Frequently asked
How much funding has Permeaderm, Inc. raised?
Permeaderm, Inc. has raised approximately $1.4M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Permeaderm, Inc.'s estimated valuation?
Provath's modeled valuation for Permeaderm, Inc. is approximately $27.6M (modeled range $267K–$313.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Permeaderm, Inc. at?
Permeaderm, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Sun Jul 01.
What does Permeaderm, Inc. do and where is it based?
Permeaderm, Inc. operates in the Biotechnology sector, based in CARLSBAD.
Explore related

See where Permeaderm, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Permeaderm, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.